TRML(Delisted)
Tourmaline Bio·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 0
Bearish signal 1
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TRML
Tourmaline Bio, Inc.
A late-stage clinical biotechnology company
27 West 24th Street, Suite 702, New York, NY 10010
--
Tourmaline Bio, Inc., is incorporated in Delaware. The company is a late-stage clinical biotechnology company with a mission to develop transformative medicines that dramatically improve the lives of patients with life-changing immune diseases. Their lead project, TOUR006, is an anti-IL-6 antibody that exhibits different properties, including high binding affinity to IL-6 and a naturally long half-life. To date, TOUR006 has studied more than 400 autoimmune patients in six clinical trials. The company plans to develop TOUR006 for the treatment of thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its primary and secondary indications, respectively, with other indications under consideration.
Company Financials
EPS
TRML has released its 2025 Q2 earnings. EPS was reported at -0.9, versus the expected -0.93, beating expectations. The chart below visualizes how TRML has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
